OMER vs III Comparison

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.